MEDULLOBLASTOMA

This study is testing a drug called Lutathera in children and young adults (ages 4 to 39) with aggressive brain or spinal cord tumors that have come back or gotten worse after standard treatments. Lutathera is a targeted radiation therapy that seeks out and attaches to specific m…

This early-stage study is testing a new, flavored, oral version of a chemotherapy drug called irinotecan (named Orotecan®) in children and young adults whose solid tumors have come back. The main goals are to find a safe and effective dose and to see how the body processes the dr…

This study is testing whether adding a drug called ibrutinib to an existing experimental treatment can help the body's immune system fight brain cancer more effectively. It is for children and young adults (ages 6-25) whose brain cancer has come back or hasn't responded to standa…

This study is testing personalized chemotherapy plans for children under 5 years old who have a type of brain cancer called medulloblastoma. Doctors will assign different treatment combinations based on the child's specific tumor type and age, aiming to control the cancer while t…

This study is testing whether a drug called DFMO, taken as a pill twice daily for two years, can help prevent the aggressive brain cancer medulloblastoma from coming back. It is for children and young adults (up to age 21) who have a high-risk form of the disease or whose cancer …

This study is testing if digoxin, a medication commonly used for heart conditions, can help control a rare and aggressive brain cancer called medulloblastoma when it has come back after initial treatment. It will involve about 23 children and young adults (ages 1-30) whose cancer…

This is the first study in people testing an experimental pill called ONC206 for adults with recurrent brain tumors that have few treatment options. The main goal is to find the highest safe dose and understand the side effects. Researchers will enroll about 102 patients to test …

This trial is testing a personalized approach for children and young adults whose brain tumors (medulloblastoma or ependymoma) have come back. Doctors test tumor tissue from surgery in a lab to see which FDA-approved drugs work best against it, and a team of experts creates a cus…

This trial provides expanded access to an experimental drug called DFMO for children and young adults (ages 0-30) with rare, relapsed cancers like neuroblastoma and medulloblastoma. The goal is to see if DFMO can help control these aggressive cancers after standard treatments hav…

This early-stage trial is testing a new type of personalized cell therapy for children and young adults whose aggressive brain tumors have come back or not responded to standard treatments. Doctors take a patient's own immune cells, genetically modify them to target a protein (GP…

This study is testing a new drug called PLX038 for adults with aggressive brain or spinal cord tumors that have returned or progressed. It focuses on tumors with specific genetic changes (MYC or MYCN) that drive cancer growth. The goal is to find a safe dose and see if the drug c…

This early-stage study is testing a new type of personalized immune therapy called B7-H3-CAR T cells for children and young adults (up to age 21) with brain tumors that have come back or haven't responded to standard treatments. The therapy involves collecting a patient's own imm…

This study is testing whether a new type of combined PET/MRI scan can help doctors better see if certain brain tumors have come back after treatment. It will involve 200 adults who have had surgery for specific brain tumors, like meningioma. The main goal is to see if this new sc…

This study follows childhood medulloblastoma survivors to understand the long-term health effects of their cancer treatments. Researchers will monitor 184 survivors who received radiation therapy at least five years ago, checking for issues like thinking problems, hearing loss, a…